#Vijaya Diagnostic IPO

[investindias]

Established in 1981, Vijaya Diagnostic Centre is one of the fastest-growing diagnostic chains in Southern India. The company offers a one-stop solution for pathology and radiology testing services. The company offers around 740 routine tests, 870 specialized pathology tests, 220 basic tests, and 320 advanced radiology tests. The company also offers a broad spectrum of customized health and wellness packages to its customers.

[srijiva-healthcare]

SriJiva Healthcare now Serves Nurses at your Home.

Book your appointments at www.srijiva.com

[wealthzi]

Vijaya Diagnostic, Ami Organics IPOs open; Should you invest?

Two IPOs have hit the street on monday, with Hyderabad based Vijaya Diagnostic and Gujarat based Ami Organics seeking to raise a combined sum of about Rs 2,500 crore. Amid the stock markets hitting new highs every day, the IPO mania continues in full swing. Here are all the details you wanted. 1. Vijaya Diagnostic Vijaya Diagnostic Centre Limited (“VDCL”) was incorporated on June 5, 2002. VDCL is the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest growing diagnostic chains by revenue for fiscal year 2020. VDCL offers an one-stop solution for pathology and radiology testing services to their customers through their extensive operational network, which comprises 80 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana; Andhra Pradesh; the National Capital Region and Kolkata.  

Vijaya Diagnostic is offering IPO shares in the price band of Rs 522 to Rs 531 per share. The face value of shares is Re 1. The implied market cap at issue price is about Rs 5,400 crore. The issue opens on September 1 and closes on September 3. The lot size for IPO application is 28 shares, which means the minimum investment is Rs 14,868. The IPO shares will be listed around September 14.  The IPO is an offer for sale of Rs 1,895 crore. The objects of the offer are to (i) carry out the OFS of up to 35,688,064 equity shares by selling shareholders; (ii) achieve the benefits of listing the equity shares on the stock exchanges. At the upper band of Rs 531, the Vijaya Diagnostic IPO is valued at P/E of 64 times its FY21 EPS of Rs 8.26. Here is what top brokers have to say about Vijaya Diagnostic IPO. IIFL Securities:  “At the upper price band, Vijaya Diagnostic Centre Limited valuation is lower than the industry average of 90.8 times. Considering the future growth potential of healthcare industry, revenue from operation, EBITDA and PAT growth of 13.5%, 23.9% and 35.5% CAGR during FY19 to FY21, respectively, strong ROE and ROCE of 23.64% and 42%, respectively in FY21, debt-free company with plans for acquisition and expansions, diversified service offerings and strong technical capabilities of the company, we recommend ‘Subscribe’ to the issue with a long-term perspective.” KR Choksey: ” Vijaya has consistently posted strong performance in terms of operating growth and profitability in last few years. Revenues have grown at a CAGR of 13.5% over FY19-21 to Rs 377 crore. VDCL’s ‘hub and spoke’ model has provided economies of scale and cost optimization benefits, resulting in EBITDA growth of 23.9% and even stronger 35.5% growth in PAT over FY19-21. Integrated network and high B2C business has translated into higher cash flow conversion. Company also recorded strong return on net worth of 23.64% and return on capital employed (pre cash) of 42.00% during FY21.” 2. Ami Organics IPO Ami Organics Limited is a research and development (“R&D”) driven manufacturer of specialty chemicals with varied end usage, focussed towards the development and manufacturing of advanced pharmaceutical intermediates (“Pharma Intermediates”) for regulated and generic active pharmaceutical ingredients (“APIs”) and New Chemical Entities (“NCE”) and key starting material for agrochemical and fine chemicals, especially from their recent acquisition of the business of Gujarat Organics Limited (“GOL”)(“Acquisition”). They are one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban. The Company have developed and commercialised over 450 Pharma Intermediates for APIs across 17 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin therapeutic areas such as anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, antidepressant and anticoagulant, for use across the global pharmaceutical market. Their Pharma Intermediates used for manufacturing of APIs and NCEs portfolio has expanded from over 425 products as of March 31, 2019, to over 450 products as of March 31, 2021.

Ami Organics is offering IPO shares in the price band of Rs 603 to 610 per share. The face value of shares is Rs 10. The issue opens on September 1 and closes on September 3. The lot size for IPO application is 24 shares, which means the minimum investment is Rs 14,640. The IPO shares will be listed around September 14.  The Ami Organics IPO comprises a fresh issue of Rs 200 crore for repayment/prepayment of certain financial facilities availed, funding working capital requirements and general corporate purposes. The other IPO component is the OFS of Rs 369.6 crore where the company will not receive any proceeds from.   With an EPS of Rs 17.14 as of 31st March 2021, the issue is priced at 35.59 times calculated at the upper price band of Rs 610 per share. The P/BV is 11.51 at a NAV of Rs 52.99 per share. Here is what top brokers have to say about Ami Organics IPO.

Anand Rathi: “The company has shown consistent financial performance with sales growth at CAGR of 19.5% and restated profit after tax growth at CAGR of 52.3% between the Fiscals 2019 and 2021. The financials for 2020- 21 doesn’t include revenue from the acquisition of the two plants. We are positive on the long-term prospects of the Company. Hence, we recommend a “Subscribe” rating to this IPO.” Marwadi Financial Services: “The competitive strengths of the company are strong and diversified product portfolio ably supported by strong R&D and process chemistry skills. Extensive geographical presence and diversified customer base with long standing relationships. High entry barriers in the chemicals manufacturing industry in which the Company operates. Strong sales and marketing capabilities. Experienced and dedicated management team. Consistent financial performance.”  

[transfin1]

Vijaya Diagnostic IPO: Facts, Stats, Opportunities and Risks

Today, the IPO of Vijaya Diagnostic Centre (VDC) opens for subscription, the 39th issue so far this year. The ₹1,895cr ($258.4m) offer is entirely an offer for sale (OFS) of 35,688,064 equity shares.

What are the facts, stats, opportunities and risks you need to know about before investing in VDC? And what do you need to know about the larger Indian diagnostics industry?

Click link to read: https://transfin.in/vijaya-diagnostic-ipo-facts-stats-opportunities-and-risks

[viral-daily]

Vijaya Diagnostic IPO open at 1 September ( Full Details)

Vijaya Diagnostic IPO Hindi News, Company,share Price,Lot size,Face Value,Dates, financial records, positive, negative, reserve

[sidnazpro2020]

Latest News Today - Kedaara-backed Vijaya Diagnostic Files IPO Papers With

Latest News Today – Kedaara-backed Vijaya Diagnostic Files IPO Papers With

Vijaya Diagnostic is one of the largest diagnostic chains in southern India Vijaya Diagnostic, the diagnostic chain backed by private equity firm Kedaara Capital, has filed the draft red herring prospectus with the market regulator Sebi for its initial public offering (IPO). Vijaya Diagnostic is the second diagnostic chain to file for IPO this year, with Krsnaa Diagnostics having filed its…

[hummingzone]

Vijaya Diagnostics IPO issue subscribed 4.5x, Ami Organics sees 64x demand

Vijaya Diagnostics IPO issue subscribed 4.5x, Ami Organics sees 64x demand

Mumbai: The preliminary public choices (IPOs) of of Vijaya Diagnostics Centre and Ami Organics closed with a subscription of 4.5 instances and 64.6 instances, respectively, on Friday. Analysts mentioned revival within the mid and smallcaps within the secondary market after a weak efficiency in August has helped these IPOs, although the market individuals favoured specialty chemical compounds…

[investyadnya]

Vijaya Diagnostic Centre Limited IPO Analysis

Vijaya Diagnostic Centre Limited IPO Analysis

Vijaya Diagnostic Centre Limited, a fast growing diagnostic service provider based on Southern India, is coming out with Rs. 1,895 Cr IPO, opening from tomorrow, 1st September, 2021. Here is a 7 point analysis of Vijaya Diagnostic Centre IPO covering IPO details, company overview, Financials, Peer comparison, Company’s strengths and Risks and the Valuation aspect. Shareholding Pattern Vijaya…

[wealthzi]

The company has shown consistent financial performance with sales growth at CAGR of 19.5% and restated profit after tax growth at CAGR of 52.3% between the Fiscals 2019 and 2021. The financials for 2020- 21 doesn’t include revenue from the acquisition of the two plants. We are positive on the long-term prospects of the Company.

[firstwatercapital]

Paytm Shares: Why blame solely Paytm? These 18 D-St debutants have tumbled 40-65%

New Delhi: Recently-listed One97 Communications, the parent company of Paytm, has been in the spotlight for eroding investor wealth. However, the stock is not an exception! 17 others have been wiping off investor money in the latest phase of correction on D-Street.

Out of 60 stocks on the BSE IPO Index, 18 stocks have dropped between 40 per cent and 65 per cent from their highs since listing. About half of the stocks in the index have wiped out one third of the investors’ wealth, the data from Ace Equity shows. 

Market experts said that the rout in global tech stocks, aggressive pricing, pure offer for sale issues, rich valuations, FII outflows, inflationary concerns and uncertainty due to the Russia-Ukraine war are adding pressure on the latest debutants. 

Ricky Kirpalani, Lead Sponsor, First Water Capital Fund (AIF) said that it is not unprecedented, as exuberance followed by a lull in the primary markets is typically seen every few years. 

“The correction in certain new listings has resulted from a deflation in IPO valuations that were stretched. Markets have been undergoing a reality check and it is not surprising that the frothiest stocks have been correcting,” he added. 

CarTrade Tech tops the losers’ list with a 66 per cent fall. The script, listed in August 2021, has dropped to Rs 547.6 on March 14, 2022 compared to its highest price of Rs 1,610.

It is accompanied by One97 Communications, which also has tanked 66 per cent to Rs 675.35 from Rs 1961.05. The company was listed in November 2021.

Listed about a year ago, Suryoday Small Finance Bank has eroded 62 per cent of the investors wealth. The script settled at Rs 112.95 on Monday from Rs 295.95 in March 2021. 

Interestingly, all the three counters were listed at discounts and have not even hit their issue price thus far. This means, the fall is more severe compared to the issue price. 

Market experts suggest that investors should reduce exposure to most new-age companies as the selling pressure could continue for a while on the back of their pricey valuations. 

Startups including Zomato and PB Fintech have eroded more than half of investors’ wealth from their recent peak. Fino Payments Bank and Krsnaa Diagnostics have also plunged more than 50 per cent. 

The recovery in stocks will depend upon the underlying business and the valuation of the stock, said Neha Khanna, Director, ValPro, a tech based investment banking platform. “There should be recovery but overpriced stocks will continue to languish.” 

Retail investors should be cautious to subscribe to IPOs only after careful analysis, cautioned Khanna. “The upside in some of the tech stocks may already be taken by venture capitalists pre-listing.” 

Paras Defense And Space Technologies, Nazara Technologies, Windlas Biotech, FSN E-Commerce Ventures (Nykaa) and Railtel Corporation of India have slipped between 45-50 per cent from their post listing peaks. 

RateGain Travel Technologies, Latent View Analytics, AGS Transact Technologies, Glenmark Life Sciences, Hindustan Media Ventures and Tega Industries are other players to fall more than 40 per cent. 

ETMarkets.com Other companies including Vijaya Diagnostics, AMI Organics, GR Infraprojects, Barbeque-Nation, Go Fashion, SJS Enterprises, Exxaro Tiles, Dodla Dairy and Laxmi Organics have wiped out one third of investors wealth from their peaks. ETMarkets.com Market participants said that understanding business fundamentals, peer comparison, the business model, strength and moats, compounding growth in revenue, sustained margins and the IPO price to understand possible upside is key. 

Akhil Rathi, Vice President Advisory at Marwadi Financial Services, said that the recovery in some of these stocks which are backed by strong products and revenue visibility in upcoming quarters is expected. 

“Investors should wait and watch the company’s upcoming earnings and outlook to enter into these stocks, ” he added. “Long term investors should accumulate the stocks in parts, as we might see continued volatility in the near future.”

 To know more information visit us:

https://www.firstwatercap.com/

[newsupdatesbykiara]

Zomato, Paytm, Nykaa and 12 other newly listed stocks hit record lows

Shares of recently listed companies came under heavy selling pressure with food delivery company Zomato, cosmetics-to-fashion retailer Nykaa, fintech major Paytm, and 12 other stocks hitting their respective all-time lows on the BSE in Monday's intra-day trade.

Data Patterns (India), Star Health and Allied Insurance Company, Vijaya Diagnostic Centre, CarTrade Tech, Dodla Dairy, Glenmark Life Sciences, Nuvoco Vistas Corporation, RailTel Corporation of India, and Suryoday Small Finance Bank, meanwhile, tanked up to 6 per cent and hit their record lows in intra-day trade as well.

At 12:55 pm, the S&P BSE Sensex was down 2 per cent or 1,276 points at 56,876 on the back of rising geopolitical tension between Russia and Ukraine. This geopolitical tension is leading to a sharp rise in crude oil prices which is another headwind for the Indian equity markets.

The S&P BSE IPO index, which slipped 3.4 per cent to 10,539 level in intra-day trade today, has corrected 23 per cent from its record high level of 13,747 touched on November 25, 2021. In comparison, the S&P BSE Sensex is down nearly 9 per cent from its all-time high level of 62,245 hit on October 19, 2021.

[techminsolutions]

Stocks to watch: Ami Organics, Vijaya Diagnostic, Infosys, D-Mart, ZEEL

Stocks to watch: Ami Organics, Vijaya Diagnostic, Infosys, D-Mart, ZEEL

Nifty futures on SGX were trading 30 points higher at 17,405 around 8.45 am, indicating a positive start for the benchmark indices on Tuesday. Here are the top stocks to track in today’s session on Dalal Street. Listing Today: Ami Organics, Vijaya Diagnostic will debut on the bourses today. The former’s IPO was subscribed 64.53 times, while the latter’s IPO was subscribed 4.54 times. Kesoram…

[salam2050]

Vijaya Diagnostic To Debut On The Bourses On Tuesday i.e. September 13

Vijaya Diagnostic To Debut On The Bourses On Tuesday i.e. September 13

Vijaya Diagnostic: The shares were sold in the price band of Rs 522-531 a share. Vijaya Diagnostic Center’s initial public offering (IPO) will list on the bourses tomorrow i.e. September 13. The Kedaara Capital-backed diagnostic chain’s was entirely an offer for sale of 35.69 million shares by existing shareholders and promoters, including Dr S Surenranath Reddy, Karakoram and Kedaara Capital…

[hummingzone]

Stocks Markets Next Week – BPCL, Emami Realty, CESC; Sansera Engineering IPO; Vijaya Diagnostic, iPhone 13, GST, retail inflation – TOP TRIGGERS

Stocks Markets Next Week – BPCL, Emami Realty, CESC; Sansera Engineering IPO; Vijaya Diagnostic, iPhone 13, GST, retail inflation – TOP TRIGGERS

Stocks Markets Next Week – The stock markets are expected to be in great action when they reopen after a long weekend on Monday. There will be enough triggers to lead the markets next week. Zee Business’ Mansi Dave gives a list of some top events that could act as triggers for the domestic markets. Stocks in News – Goldiam International Limited shares – The company will be holding a board meeting…

[letsjanukhan]

UPDATE: How To Check Share Allotment Status

UPDATE: How To Check Share Allotment Status

<!– –> Vijaya Diagnostic shares are likely to be listed on September 14, 2021 Vijaya Diagnostic will finalize the share allotment tomorrow i.e. September 8, 2021. The diagnostic chain company’s initial public offering (IPO) was subscribed 4.54 times, receiving bids for 11.36 crore shares against 2.50 crore shares on offer. The shares are likely to be listed on September 14, 2021. The Kedaara…